On October 8, WUXI BIO fell 3.26% in regular trading, trading at HK$54.85 with turnover of HK$1.045 billion.

The decline came as the broader biopharmaceutical sector faced collective pressure. The Hang Seng Biotechnology Index had plunged 3.15% the prior day, with GenScript Biotech tumbling over 14%, setting a negative tone that weighed heavily on WUXI BIO. CXO concept stocks underwent a broad correction as short-term profit-taking intensified following the sector's recovery since June.

Despite solid fundamentals including first-half revenue of RMB11.787 billion, adjusted net profit of RMB3.937 billion, and gross margin improvement to 46.2%, investors chose to lock in gains after the recent rally. The XDC segment showed strong external sales growth of 37.8% year-over-year, but this failed to offset near-term selling pressure driven by sector-wide sentiment deterioration.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)